Page 126 - 中国全科医学2022-20

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·2555·

metformin achieved sustained efficacy and good safety profiles in T2D dose selection［J］. ClinTranslSci，2017，10（5）：404-411.
patients in a 52-week phase 3 trial （DAWN）［J］. Diabetes， DOI：10.1111/cts.12479.
2021，70（Supplement 1）. DOI：10.2337/db21-763-p. ［19］CAMPBELL J E，DRUCKER D J. Pharmacology，physiology，and
［8］ZHU D L，GAN S L，LIU Y，et al. Dorzagliatin monotherapy mechanisms of incretin hormone action［J］. Cell Metab，2013，17（6）：
in Chinese patients with type 2 diabetes：a dose-ranging， 819-837. DOI：10.1016/j.cmet.2013.04.008.
randomised，double-blind，placebo-controlled，phase 2 ［20］LUDVIK B，GIORGINO F，JÓDAR E，et al. Once-weekly
study［J］. Lancet Diabetes Endocrinol，2018，6（8）：627-636. tirzepatide versus once-daily insulin degludec as add-on to
DOI：10.1016/S2213-8587（18）30105-0. metformin with or without SGLT2 inhibitors in patients with type 2
［9］ZHENG S，SHAO F，DING Y，et al. Safety，pharmacokinetics， diabetes （SURPASS-3）：a randomised，open-label，parallel-
and pharmacodynamics of globalagliatin，a glucokinase activator，in group，phase 3 trial［J］. Lancet，2021，398（10300）：583-
Chinese patients with type 2 diabetes mellitus：arandomized，phase 598. DOI：10.1016/S0140-6736（21）01443-4.
ib，28-day ascending dose study［J］. Clin Drug Investig，2020， ［21］TILLNER J，POSCH M G，WAGNER F，et al. A novel dual
40（12）：1155-1166. DOI：10.1007/s40261-020-00971-x. glucagon-like peptide and glucagon receptor agonist SAR425899：
［10］BONADONNA R C，HEISE T，ARBET-ENGELS C，et al. results of randomized，placebo-controlled first-in-human and first-
Piragliatin （RO4389620），a novel glucokinase activator，lowers in-patient trials［J］. Diabetes Obes Metab，2019，21（1）：
plasma glucose both in the postabsorptive state and after a glucose 120-128. DOI：10.1111/dom.13494.
challenge in patients with type 2 diabetes mellitus：amechanistic ［22］VISENTIN R，SCHIAVON M，GÖBEL B，et al. Dual glucagon-
study［J］. J Clin Endocrinol Metab，2010，95（11）：5028- like peptide-1 receptor/glucagon receptor agonist SAR425899
5036. DOI：10.1210/jc.2010-1041. improves beta-cell function in type 2 diabetes［J］. Diabetes Obes
［11］SARABU R，BIZZARRO F T，CORBETT W L，et al. Discovery Metab，2020，22（4）：640-647. DOI：10.1111/dom.13939.
of piragliatin—first glucokinase activator studied in type 2 diabetic ［23］NAHRA R，WANG T，GADDE K M，et al. Effects of cotadutide
patients［J］. J Med Chem，2012，55（16）：7021-7036. on metabolic and hepatic parameters in adults with overweight or
DOI：10.1021/jm3008689. obesity and type 2 diabetes：a 54-week randomized phase 2b
［12］ZHI J G，ZHAI S P，BOLDRIN M. Dose-dependent effect of study［J］. Diabetes Care，2021，44（6）：1433-1442. DOI：
piragliatin，a glucokinase activator，on the QT interval following 10.2337/dc20-2151.
short-term multiple doses in patients with type 2 diabetes ［24］ASANO M，SEKIKAWA A，KIM H，et al. Pharmacokinetics，
mellitus［J］. Clin Pharmacol Drug Dev，2017，6（3）：258- safety，tolerability and efficacy of cotadutide，a glucagon-like
265. DOI：10.1002/cpdd.289. peptide-1 and glucagon receptor dual agonist，in phase 1 and 2
［13］POITOUT V，LIN D C H. Modulating GPR40：therapeutic promise trials in overweight or obese participants of Asian descent with or
and potential in diabetes［J］. Drug Discov Today，2013，18（23/24）： without type 2 diabetes［J］. Diabetes Obes Metab，2021，23（8）：
1301-1308. DOI：10.1016/j.drudis.2013.09.003. 1859-1867. DOI：10.1111/dom.14412.
［14］YAMADA H，YOSHIDA M，ITO K，et al. Potentiation of glucose- ［25］DARBALAEI S，YULIANTIEE，DAIA T，et al. Evaluation of
stimulated insulin secretion by the GPR40-PLC-TRPC pathway biased agonism mediated by dual agonists of the GLP-1 and glucagon
in pancreatic β-cells［J］. Sci Rep，2016，6：25912. DOI： receptors［J］. Biochem Pharmacol，2020，180：114150. DOI：
10.1038/srep25912. 10.1016/j.bcp.2020.114150.
［15］MENON V，LINCOFF A M，NICHOLLS S J，et al. Fasiglifam- ［26］WYNNE K，PARK A J，SMALL C J，et al. Oxyntomodulin
induced liver injury in patients with type 2 diabetes：results of a increases energy expenditure in addition to decreasing energy
randomized controlled cardiovascular outcomes safety trial［J］. intake in overweight and obese humans：a randomised controlled
Diabetes Care，2018，41（12）：2603-2609. DOI：10.2337/ trial［J］. Int J Obes （Lond），2006，30（12）：1729-1736.
dc18-0755. DOI：10.1038/sj.ijo.0803344.
［16］BAZYDLO-GUZENDA K，BUDA P，MACH M，et al. Evaluation ［27］COHEN M A，ELLIS S M，LE ROUX C W，et al. Oxyntomodulin
of the hepatotoxicity of the novel GPR40 （FFAR1） agonist suppresses appetite and reduces food intake in humans［J］. J Clin
CPL207280 in the rat and monkey［J］. PLoS One，2021，16（9）： Endocrinol Metab，2003，88（10）：4696-4701. DOI：10.1210/
e0257477. DOI：10.1371/journal.pone.0257477. jc.2003-030421.
［17］BAZYDLO-GUZENDA K，BUDA P，MATLOKA M，et al. ［28］WYNNE K，PARK A J，SMALL C J，et al. Subcutaneous
CPL207280，a novel G protein-coupled receptor 40/free fatty oxyntomodulin reduces body weight in overweight and
acid receptor 1-specific agonist，shows a favorable safety profile obese subjects：a double-blind，randomized，controlled
and exerts antidiabetic effects in type 2 diabetic animals［J］. trial［J］. Diabetes，2005，54（8）：2390-2395. DOI：
Mol Pharmacol，2021，100（4）：335-347. DOI： 10.2337/diabetes.54.8.2390.
10.1124/molpharm.121.000260. ［29］SHANKAR S S，SHANKAR R R，MIXSON L A，et al. Native
［18］KRUG A W，VADDADY P，RAILKAR R A，et al. Leveraging a oxyntomodulin has significant glucoregulatory effects independent of
clinical phase ib proof-of-concept study for the GPR40 agonist MK- weight loss in obese humans with and without type 2 diabetes［J］.
8666 in patients with type 2 diabetes for model-informed phase Ⅱ Diabetes，2018，67（6）：1105-1112. DOI：10.2337/db17-